In 1990 the National Institutes of Health Consensus Conference recommended adjuvant combined therapy for patients with radically resected rectal cancer at high risk for relapse (ie, stage II-III). The purpose of our prospective non-randomized study was to verify the feasibility and effectiveness of postoperative radiochemotherapy in terms of improvement in disease-free and overall survival in this patient subgroup.
Study design
From January 1990 to October 1998, 191 consecutive patients with radically resected stage II-III rectal cancer were treated. A total of 159 patients with a 24-month follow-up were assessable for toxicity and survival. Anterior resection was performed in 129 (81%) and abdomino-perineal resection in 30 (19%) patients. Fifty-four (34%) stage II and 105 (66%) stage III patients entered the study. Within 45-60 days of surgery, all patients received 5-fluorouracil chemotherapy at the dose of 500 mg/m2 as an iv bolus on days 1-5, every 4 weeks, for 6 cycles. Chemotherapy cycles III and IV were administered at the same daily dose on radiotherapy days 1-3 and 29-31. Radiotherapy consisted of 45 Gy/25 fractions plus a boost dose of 5.4 Gy.
Results
After a median follow-up of 57 months (range, 25-123), overall recurrent disease was reported in 58 (36%) patients: local, systemic, and both local and systemic relapses in 12 (8%), 37 (23%) and 9 (6%) cases, respectively. According to local extension, recurrence rates were 15% and 48% in stage II and III, respectively. Five-year overall and disease-free survival were 71% and 66%, respectively. Overall survival was 87% in stage II and 62% in stage III patients, and disease-free survival was 84% and 56% in stage II and III disease, respectively. According to univariate and multivariate analyses, significant prognostic factors for better tumor control were: stage (II vs III, P <0.001), the number of involved nodes (≤3 vs >3, P <0.0001), and no extracapsular node invasion (P <0.0001). The recommended dose of the combined radiochemotherapy regimen was generally well tolerated. The incidence of any ≥ grade 3 acute toxicity (according to the WHO scale) was 13% diarrhea, 11% proctitis, 5% perineal dermatitis and 4% myelosuppression. Four (3%) patients had radiotherapy-related severe late toxicity which required surgery.
Conclusions
The study provided recurrence rates and survival similar to other adjuvant radiochemotherapy regimens published in the literature. However, in view of the low 5-year survival rate recorded in stage III patients, a different approach should be investigated.
De CarliA., La VecchiaC.: Cancer Mortality in Italy, 1993.Tumori, 83: 643–649, 1997.
2.
FreedmanG.M., CoiaL.R.: Adjuvant and neoadjuvant treatment of rectal cancer.Semin Oncol, 22: 611–624, 1995.
3.
VenookA., GoodnightJ., KumarS., TaylorC., GildenR., FiglinR.A.: Practice guidelines for colorectal cancer.Cancer J, 2: S23–S36, 1996.
4.
GundersonL.L., SosinH.: Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum: clinico-patholog-ic correlation and implications for adjuvant therapy.Cancer, 34: 1278–1292, 1974.
5.
EisenbergB., De CosseJ.J., HarfordF., MichalekJ.: Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients.Cancer, 49: 1131–1134, 1982.
6.
EnkerW.E., LafferU.T., BlockG.E.: Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection.Ann Surg, 68: 836–837, 1979.
7.
FisherB., WolmarkN., RocketteH., RedmondC., DeutschM., WickerhamD.L., FisherE.R., CaplanR., JonesJ., LernerH.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.J Natl Cancer Inst, 80: 21–29, 1988.
8.
Gastrointestinal Tumor Study Group.Prolongation of the disease-free interval in surgically treated rectal carcinoma.N Engl J Med, 312: 1465–1472, 1985.
9.
Gastrointestinal Tumor Study Group.Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum.J Clin Oncol, 10: 549–557, 1992.
10.
MendenhallW.M., RodneyR.M., PfaffW.: Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy.Int J Radiat Oncol Biol Phys, 9: 977–985, 1983.
11.
MinskyB.D., MiesC., RechtA., RichT.A., ChaffeyJ.T.: Resectable adenocarcinoma of the rectosigmoid and rectum. Patterns of failure and survival.Cancer, 61: 1408–1416, 1988.
12.
PihlE., HuguesE.S.R., McDermottF.T., MilmeB.J., KornerJ.M.N., PriceA.B.: Carcinoma of the rectum and rectosigmoid: cancer specific long-term survival. A series of 1061 cases treated by one surgeon.Cancer, 53: 2902–2907, 1984.
13.
PilipshenS.J., HeilweilM., QuanS.H.Q., SternbergS.S., EnkerW.E.: Pattern of pelvic recurrence following definitive resections of rectal cancer.Cancer, 53: 1354–1362, 1984.
14.
RichT.A., GundersonL.L., LewR., GaldibiniJ.J., CohenA.M., DonaldsonG.: Patterns of recurrence of rectal cancer after potentially curative surgery.Cancer, 52: 1317–1329, 1983.
15.
RichT.A., TerryN.H.A., MeistrichM., ClearyK., OtaD.: Pathologic, anatomic and biologic factors correlated with local recurrence of colorectal cancer.Semin Radiat Oncol, 3: 13–19, 1993.
16.
BalslevI., PedersonM., TeglbjaergP.S., Hanberg-SoerensenF., BoneJ., JacobsenN.O., OvergaardJ., SellA., BertelsenK., HageE., FengerC., KronborgO., HansenL., HoestrupH., Noergard-PedersenB.: Postoperative radiotherapy in Duke'B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study.Cancer, 58: 22–28, 1986.
17.
DouglassH.O., MoertelC.G.(on behalf of the Gastrointestinal Tumor Study Group). Survival after postoperative combination treatment of rectal cancer.N Engl J Med, 315: 1294–1295, 1986.
Treurniet-DonkerA.D., Van PuttenW.L.J., WereldsmaJ.C.J., BrugginkE.D.M., HoogenraadW.J., RoukemeJ.A., Snijders-KeilholzA., MeijerW.S., MeerwaldtJ.H., WijnmaalenA.J., WiggersT.: Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in the Netherlands.Cancer, 67: 2042–2048, 1991.
20.
Randomized trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum.Medical Research Council Rectal Cancer Working Party.Lancet, 348: 1610–1614, 1996.
21.
ArnaudJ.P., NordlingerB., BossetJ.F., Hoctin BoesG., SahmondT., SchlagP.M., PeneF.: Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer.Br J Surg, 84: 352–357, 1997.
22.
National Institutes of Health Consensus Conference.Adjuvant therapy for patients with colon and rectal cancer.JAMA, 264: 1444–1450, 1990.
23.
ICRU report 50: Prescribing, recording and reporting photon beam therapy: Bethesda, Maryland.International Commission on Radiation Units and Measurements, 1993.
24.
GallagherM.J., BreretonH.D., RostockR.A., ZeroJ.M., ZekoskiD.A., PoyssL., RichterM.P., KligermanM.M.: A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation.Int J Radiat Oncol Biol Phys, 12: 1565–1573, 1986.
25.
ShanananT.G., MehtaM.P., BertelrudK.L., BuchlerD.A., FrankL.E., GehringM.A., KubsadS.S., UtrieP.C., KinsellaT.J.: Minimization of small bowel volume within treatment fields utilizing customized “belly board”.Int J Radiat Oncol Biol Phys, 19: 469–476, 1990.
BentzenS.M., BalslevI., PedersenM., TeglbjaergP.S., Hanberg SorensenF., BoneJ., JacobsenN.O., SellA., OvergaardJ., BertelsenK.: Time to loco-regional recurrence after resection of Dukes’ B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis.Br J Cancer, 65: 102–107, 1992.
28.
RosenthalS.A., TrockB.J., CoiaL.R.: Randomized trials of adjuvant radiation therapy for rectal carcinoma.A review. Dis Colon Rectum, 33: 335–343, 1990.
29.
O'ConnellM.J., MartensonJ.A., WieandH.S., KrookJ.E., MacDonaldJ.S., HallerD.G., MayerR.J., GundersonL.L., RichT.A.: nproving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.N Engl J Med, 331: 502–507, 1994.
30.
ByfieldJ.F., Calabro-JonesP., KlisakI., KulhanianF.: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combine 5-fluorouracil for ftorafur and X-rays.Int J Radiat Oncol Biol Phys, 8: 1923–1933, 1982.
TveitK.M., GuldvogI., HagenS., TrondsenE., HarbitzT., NygaardK., NilsenJ.B., WistE., HannisdalE.on behalf of the Norwegian Adjuvant Rectal Cancer Project Group: Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes’ B and C rectal cancer.Br J Surg, 84: 1130–1135, 1997.
33.
FountzilasG., ZisiadisA., DafniU., KonstantarasC., Hatzitheo-harisG., LiarosA., AthanassiouE., DombrosN., DervenisC., BasdanisG., GamvrosO., SouparisA., BriasoulisE., SamantasE., KappasA., KosmidisP., SkarlosD., PavlidisN.: Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.Ann Oncol, 10: 671–676, 1999.
34.
LupattelliM., MaranzanoE., TrancanelliV., BelsantiV., PinagliaD., BeneventiS., LatiniP.: Adjuvant radiochemotherapy in radically resected high risk rectal cancer. Preliminary results of a prospective trial.Radiol Med, 95: 86–92, 1998.
35.
CioniniL., MarzanoS., BoffiL., CardonaG., FicariF., FuciniC., TonelliF.: Adjuvant postoperative radiotherapy in rectal cancer: 148 cases treated at Florence University with 8 year median follow-up.Radiother Oncol, 40: 127–135, 1996.
36.
SchildS.E., MartensonJ.A.Jr, GundersonL.L., IlstrupD.M., BergK.K., O'ConnellM.J., WielandL.H.: Postoperative adjuvant therapy of rectal cancer: an analysis of disease control, survival, and prognostic factors.Int J Radiat Oncol Biol Phys, 17: 55–62, 1989.
37.
TakahashiT., KatoT., KodairaS., KoyamaT., SakabeT., Tomi-nagaT., HamanoK., YasutomiM., OgawaN.: Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection. Cases with or without adjuvant chemotherapy.Am J Clin Oncol, 19: 408–415, 1996.
38.
MartijnH., De NeveW., LybeertM.L.M., CrommelinM.A., Ri-botJ.G.: Adjuvant postoperative radiotherapy for adenocarcinoma of the rectum and rectosigmoid. A retrospective analysis of locoregional control, survival, and prognostic factors on 178 patients.Am J Clin Oncol, 18: 277–281, 1995.
39.
MohiuddinM., RegineW.F., MarksG.: Prognostic significance of tumor fixation of rectal carcinoma. Implications for adjunctive radiation therapy.Cancer, 78: 717–722, 1996.
BossetJ.F., HoriotJ.C.: Adjuvant treatment in the curative management of rectal cancer: a critical review of the results of clinical randomized trials.Eur J Cancer, 29: 770–774, 1993.
42.
AlemanB.M.P., BartelinkH., GundersonL.L.: The current role of radiotherapy in colorectal cancer.Eur J Cancer, 31: 1333–1339, 1995.
43.
LetschertJ.G.J.: The prevention of radiation-induced small bowel complications.Eur J Cancer, 31A: 1361–1365, 1995.
44.
MakA.C., RichT.A., Schult HeissT.E., KavanaghB., OtaD.M., RomsdahlM.M.: Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid.Int J Radiat Oncol Biol Phys, 28: 597–603, 1994.
45.
OoiB.S., TjandraJ.J., GreenM.D.: Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview.Dis Colon Rectum, 42: 403–418, 1999.
46.
GundersonL.L., RussellA.H., LiewellynH.J., DoppkeK.P., TepperJ.E.: Treatment planning for colorectal cancer: radiation and surgical techniques and value of small-bowel films.Int J Radiat Oncol Biol Phys, 11: 1379–1393, 1985.
47.
HealdR.J., KaranjiaN.D.: Results of radical surgery for rectal cancer.World J Surg, 16: 848–857, 1992.
EnkerWE: Designing the optimal surgery for rectal carcinoma.Cancer, 78: 1847-1850, 1996.
50.
WolmarkN, WieandS, HyamsDM, ColangeloL, DimitrovNV, RomondEH, WexlerM, PragerD, CruzAB Jr, GordonPH, Pe-trelliNJ, DeutschM, MamounasE, WickerhamDL, FisherER, RocketteH, FisherB: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.J Natl Cancer Inst, 92: 388-396, 2000.
51.
Swedish Rectal Cancer Trial.Improved survival with preoperative radiotherapy in resectable rectal cancer.N Engl J Med, 336: 980-987,1997.
52.
ChariRS, TylerDS, AnscherMS, RussellL, ClaryBM, HathornJ, SeiglerHF: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.Ann Surg, 221:778-786, 1995.
53.
GrannA, MinskyBD, CohenAM, SaltzL, GuillenJG, PatyPB, KelsenDP, KemenyN, IlsonD, Boss-LoebJ: Preliminary results of preoperative 5-fluorouracil, low-dose leucov-orin and concurrent radiation therapy for clinically resectable T3 rectal cancer.Dis Colon Rectum, 40: 515-522, 1997.
PahlmanL, GlimeliusB: Preoperative radiotherapy is better than postoperative radiotherapy in patients with rectal cancer.Gastroenterology, 99: 895-897, 1990.
57.
ValentiniV, MorgantiAG, FiorentinoG, LuziS, SmaniottoD, TurrizianiA, RattoC, SofoL, DogliettoGB, CelliniN: Chemoradiation with raltitrexed (tomudex) and concomitant preoperative radiotherapy has potential in the treatment of stage II/III resectable rectal cancer (Abstr).Proc ASCO, 18: 987, 1999.
58.
TeicherBA, AraG, ChenYN, RechtA, ColemanCN: Interaction of tomudex with radiation in vitro and in vivo.Int J Oncol, 13: 437-442, 1998.
59.
JamesR, PriceP, ValentiniV: Raltitrexed (tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.Eur J Cancer, 35: S19-22, 1999.
